Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.

Supporters

Support the authors with ResearchCoin

Tip RSC

Preprint Server

Topics

Biology

Immunology

Medicine

Internal Medicine

Disease

Show all topics

DOI

10.1101/2021.06.09.447722

License

CC-BY-NC

Other Formats

PDF